Vistin Pharma reports 11% revenue growth in Q2

Vistin Pharma reported Q2 2025 revenue of MNOK 118, an 11% increase from MNOK 106 in Q2 2024, driven by a 17% rise in sales volumes.

EBITDA for Q2 increased 11% to MNOK 30. Year-to-date EBITDA climbed 27% to MNOK 60, with net profit of MNOK 40.2 for the first half. The company paid a cash dividend of NOK 1.25 per share in June.